دورية أكاديمية
Inhibiteurs des SGLT2 et risque d'amputations des membres inférieurs: plus de peur que de mal ?
| العنوان: | Inhibiteurs des SGLT2 et risque d'amputations des membres inférieurs: plus de peur que de mal ? SGLT2 inhibitors and risk of lower-limb amputations: More fear than harm? |
|---|---|
| المؤلفون: | Scheen, André |
| المصدر: | Médecine des Maladies Métaboliques, 16 (4), 336 - 342 (2022) |
| بيانات النشر: | Elsevier Masson s.r.l., 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Amputation, DPP-4 inhibitor, Gliflozin, GLP-1, Peripheral arteriopathy, Type 2 diabetes, dipeptidyl peptidase IV inhibitor, glucagon like peptide 1 receptor agonist, placebo, sodium glucose cotransporter 2 inhibitor, Article, drug safety, fear, human, leg amputation, non insulin dependent diabetes mellitus, pharmacovigilance, randomized controlled trial (topic), risk, risk reduction, Human health sciences, Endocrinology, metabolism & nutrition, Pharmacy, pharmacology & toxicology, Sciences de la santé humaine, Endocrinologie, métabolisme & nutrition, Pharmacie, pharmacologie & toxicologie |
| الوصف: | For the last five years, a potential increased risk of lower-limb amputation (LLA) among patients with type 2 diabetes treated with sodium-glucose cotransporter type 2 inhibitors (SGLT2is) has been a matter of debate. The present article traces the history of this controversy since the landmark publication of CANVAS until the last observational studies in real life. Despite the warnings that emerged from pharmacovigilance reports, neither prospective randomized placebo-controlled trials nor large cohort retrospective observational studies vs. dipeptidyl peptidase-4 inhibitors were able to demonstrate a significant increased risk of LLA among new SGLT2i users. The higher incidence of LLA when compared to glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which is commonly interpreted as an increased risk associated with SGLT2is, might rather reflect a reduction of the risk of LLA with GLP-1 ARs. Overall, available data regarding the risk of LLA with SGLT2is should reassure clinicians, even if some circumstances should call for caution. © 2022 Elsevier Masson SAS |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | urn:issn:1957-2557; urn:issn:2214-8477 |
| DOI: | 10.1016/j.mmm.2022.01.015 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/300354Test |
| حقوق: | restricted access http://purl.org/coar/access_right/c_16ecTest info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsorb.300354 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1016/j.mmm.2022.01.015 |
|---|